Skip to main content

Fiscal Wizard · Single-issue tearsheet

MNPR / Jun 20, 2026 Run #7240

MNPR

Monopar Therapeutics Inc.

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; Excel Diagnostics and Nuclear Oncology Center, for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu; license agreement with Alexion to develop and commercialize ALXN1840, a drug candidate for Wilson disease. The company was founded in 2014 and is headquartered in Wilmette, Illinois.

Composite verdict

F 13.9 / 100
Bearish setup · Mean Reversion 9 drivers · 3 gates blocking
  • Chaikin Money Flow
  • Vortex Signal
  • Connors RSI(2)
Consider long put target Δ ~0.70 · ~35 DTE Bearish setup, Grade A → ITM put target

Industry rank 380th of 598 in Biotechnology

rescore-sweep
Technical synthesisRegime: range
Bull 0%Evidence: High · 21 signals100% Bear
Momentum Bearish 16Mean-reversion Bearish 37

No notable composite patterns — the signals don't cluster into a named setup right now.

Where value comes fromMargin of safety -85%

Earnings power doesn't cover the capital structure (high debt) — the EPV decomposition isn't meaningful for this name.

Fundamentals Weak

27.7 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
Greenblatt ROC 79
Margin of Safety 0
Return on Capital Employed 79
Free Cash Flow Yield 0
Return on Assets 78
EPS Growth (YoY) 0

Technicals Bearish

0.1 / 100

Bearish setup leads (Chaikin Money Flow, Vortex Signal, Connors RSI(2)); bulls gated by guards. · 43 signals shown.

Strongest
Weakest
Chaikin Money Flow 8
Vortex Signal 10
Coppock Curve 12

Risk Gates

3 blocking 6 caution

3 guards active, 19 signals gated.

Piotroski F-Score Blocking

Bottom-band Piotroski F blocks bullish signals — fundamental-quality risk.

ADX Trend Weakness Blocking

Weak trend strength blocks trend-following signals in either direction.

Regime Filter Blocking

Blocks signals that oppose the long-term moving-average regime.

Cash Ratio Caution

Visual cash-cushion flag — does not mute signals.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for MNPR.